Sep
27
2020
Boehringer’s schizophrenia med boosts cognition in phase 2
Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or …